UK antitrust case trackers

The following documents summarise and track ongoing and completed antitrust (behavioural) investigations by the CMA, sectoral regulator and the former OFT and subsequent appeals before the CAT and higher courts in relation to (1) the Competition Act 1998 and/or Articles 101/102 TFEU, (2) the

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Competition News

UK Competition law—daily round-up (21/11/2024)

A round-up of UK competition law developments, including (amongst other things) the CMA’s response to the Government's Industrial Strategy Green Paper and publishes speech by Sarah Cardell on how the CMA ‘is rising to the challenge on growth’.

EU Competition law—daily round-up (21/11/2024)

A round-up of EU competition law developments, including (amongst other things) the latest EUMR and State aid developments.

Competition weekly highlights—21 November 2024

This week's edition of Competition weekly highlights includes, from a UK perspective: (1) the CMA refers to phase 2 with the following mergers: Boparan/ForFarmers (Burston and Radstock mills) and GXO/Wincanton, (2) the CAT’s judgment setting aside CMA’s remittal in Pfizer/Flynn phenytoin sodium capsules investigation, remaking the decision and imposing fines largely matching those previously issued by the CMA, and (3) the CMA’s decision to launch a consultation on draft new guidance for road fuel monitoring. This week's highlights also includes, from an EU perspective: (1) the Commission’s decision to fine Meta €797m for Facebook Marketplace abuses, and (2) the Commission’s announcement that Booking.com must comply with all relevant obligations under the Digital Markets Act.

UK Competition law—daily round-up (20/11/2024)

A round-up of UK competition law developments, including (amongst other things) (1) the CMA’s announcement that it has referred to phase 2 the Boparan/ForFarmers (Burston and Radstock mills) merger, and (2) the CAT’s judgment setting aside CMA’s remittal in Pfizer/Flynn phenytoin sodium capsules investigation, remaking the decision and imposing fines largely matching those previously issued by the CMA.